vTv Therapeutics (VTVT) Income from Continuing Operations: 2013-2024
Historic Income from Continuing Operations for vTv Therapeutics (VTVT) over the last 12 years, with Dec 2024 value amounting to -$22.7 million.
- vTv Therapeutics' Income from Continuing Operations fell 77.14% to -$10.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$28.4 million, marking a year-over-year decrease of 24.97%. This contributed to the annual value of -$22.7 million for FY2024, which is 12.56% up from last year.
- Per vTv Therapeutics' latest filing, its Income from Continuing Operations stood at -$22.7 million for FY2024, which was up 12.56% from -$26.0 million recorded in FY2023.
- In the past 5 years, vTv Therapeutics' Income from Continuing Operations registered a high of -$12.8 million during FY2020, and its lowest value of -$26.0 million during FY2023.
- For the 3-year period, vTv Therapeutics' Income from Continuing Operations averaged around -$24.6 million, with its median value being -$25.1 million (2022).
- In the last 5 years, vTv Therapeutics' Income from Continuing Operations spiked by 41.64% in 2020 and then plummeted by 41.41% in 2022.
- Yearly analysis of 5 years shows vTv Therapeutics' Income from Continuing Operations stood at -$12.8 million in 2020, then plummeted by 38.50% to -$17.7 million in 2021, then tumbled by 41.41% to -$25.1 million in 2022, then dropped by 3.56% to -$26.0 million in 2023, then climbed by 12.56% to -$22.7 million in 2024.